PrEPVacc, NCT04066881: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP |
|
|
| Enrolling by invitation | 2b | 1668 | RoW | Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48), Control PrEP:TDF/FTC once daily (weeks 0-26), Truvada, Experimental PrEP:TAF/FTC once daily (weeks 0-26), Descovy | MRC/UVRI and LSHTM Uganda Research Unit, Imperial College London, University College, London, International AIDS Vaccine Initiative, EuroVacc Foundation, Medical Research Council, South Africa, National Institute for Medical Research, Tanzania, Muhimbili University of Health and Allied Sciences, Instituto Nacional de Saúde, Mozambique, Ludwig-Maximilians - University of Munich, King's College London, Centre Hospitalier Universitaire Vaudois, Karolinska Institutet, CONRAD, Gilead Sciences | HIV Infections | 12/24 | 12/24 | | |
| Active, not recruiting | 1 | 88 | RoW | Vaccine, Placebo | University of Oxford, European and Developing Countries Clinical Trials Partnership (EDCTP), University of Nairobi, KEMRI-Wellcome Trust Collaborative Research Program, MRC/UVRI & LSHTM Uganda Research Unit, International AIDS Vaccine Initiative, Imperial College London, Center for Family Health Research in Zambia | HIV-1-infection | 11/22 | 11/22 | | |
| Recruiting | N/A | 1440 | RoW | Abbott HIV-1/2 VL Point of care Device | MRC/UVRI and LSHTM Uganda Research Unit, Karolinska Institutet, Kilimanjaro Christian Medical Centre, Tanzania, Amsterdam Institute for Global Health and Development, National Institute for Medical Research, Tanzania, Kenya Medical Research Institute, University of Rwanda | HIV, Viral Load, Point of Care Monitoring | 08/24 | 02/25 | | |
